Author:
Xiong Yue,Cui Xiaochuan,Zhou Yanjun,Chai Gaoshang,Jiang Xiufeng,Ge Guizhi,Wang Yue,Sun Hongxu,Che Huilian,Nie Yunjuan,Zhao Peng
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference46 articles.
1. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011
2. Lung transplantation in idiopathic pulmonary fibrosis;Kumar;Expert. Rev. Respir. Med.,2018
3. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis;Yoon;Respir. Res.,2018
4. Evidence-based treatment strategies in idiopathic pulmonary fibrosis;Behr;Eur. Respir. Rev.,2013
5. P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, D. Kardatzke, T.E. King, Jr., L. Lancaster, S.A. Sahn, J. Szwarcberg, D. Valeyre, R.M. du Bois, C.S. Group, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet 377(9779) (2011) 1760–1769.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献